EASD
EASD President Francesco Giorgino previews EASD 2026, discussing the key developments set to shape diabetes research and care, including incretin therapies, type 1 diabetes, AI and diabetes technology, personalized care, screening, and his priorities for EASD during his presidency.
In this touchENDOCRINOLOGY Future Leaders 2026 Q&A, Dr Simon Berry (Sheffield, UK) reflects on the experiences that led him into diabetes and endocrinology, the mentors who have influenced his clinical and academic journey, and the innovations he believes are set to transform patient care. From advances in immunotherapy and islet transplantation to the evolving landscape of diabetes treatment, Simon shares his perspectives on the opportunities ahead for the specialty.
Dr Ahmed Iqbal joins the touchREVIEWS in Endocrinology Editorial Board, bringing expertise in hypoglycaemia and personalized diabetes care.
The European Association for the Study of Diabetes (EASD) Early Career Academy (ECA) has rapidly become a central initiative supporting the professional development of emerging clinicians and researchers in diabetology. Established to foster mentorship, collaboration and career progression, the Academy ...
Post-bariatric weight regain is a major clinical challenge. In the BARI-STEP trial, semaglutide 2.4 mg weekly led to substantial, sustained weight loss and improved cardiometabolic health. Dr Janine Makarondis discusses the findings and the potential of GLP-1 therapy in this patient population.
ObesityWeek® 2025 highlighted obesity as a chronic, multi-system disease that links cardiovascular, renal, and metabolic health. New data from clinical trials showcased therapies improving weight, blood pressure, and inflammation, signalling a shift toward integrated care where obesity management becomes central to cardiovascular-kidney-metabolic health.
Dr John Doupis shares his highlights from EASD 2025, discussing breakthrough trials in diabetes and obesity, emerging therapies, and how advancing technology and AI are reshaping the future of diabetes care.
Dr Peter Gillard discusses results from the RADIANT extension study, showing sustained benefits of the Omnipod 5 AID system for people with type 1 diabetes.
Dr Thinzar Min discusses how the Enhanced Liver Fibrosis (ELF) test could help detect liver fibrosis and assess cardiovascular risk in people with type 2 diabetes.
TouchENDOCRINOLOGY coverage from EASD 2025: At the EASD 2025 congress (Vienna, Austria; 15–19 September), new research from the University of Sheffield explored the potential role of tirzepatide as an adjunctive therapy in people with type 1 diabetes and obesity. Tirzepatide, a dual GIP and ...
We spoke with Dr Garvey at EASD 2025 to learn more about the mechanism of action of cagrilintide, the design and outcomes of the REDEFINE 1 analysis, and the future directions for this promising therapeutic option.
In this interview, Professor Ketan Dhatariya discusses why inpatient diabetes is now a priority, the opportunities and barriers for CGM, and his vision for improving hospital care.
At EASD 2025, the phase 2 TIRTLE1 trial showed tirzepatide significantly reduced weight, insulin needs and improved glycaemic control in adults with type 1 diabetes and obesity. In this interview, Dr Jennifer Snaith discusses the findings and clinical implications.
This Q&A with Dr Paul Brennan offers a practical guide to the diagnosis and management of metabolic dysfunction-associated steatohepatitis (MASH). Covering key risk factors, non-invasive diagnostic tools, lifestyle strategies, and emerging therapies, it provides clinicians with clear approaches to early detection and comprehensive patient care.
touchENDOCRINOLOGY was delighted to speak with Editorial Board member Dr Deep Dutta, a senior endocrinologist at the CEDAR Superspecialty Clinics, New Delhi, India. Throughout this interview, he summarizes the key messages from his late-breaking abstract session ‘Ailing Heart, Broken Vessels’, presented at the 60th European Association for the Study of Diabetes (EASD) annual meeting in Madrid, Spain.
In this expert Q&A we are delighted to welcome our Editorial Board member Dr Sanjay Kalra, a leading endocrinologist with over two decades of experience at Bharti Hospital, Karnal, India. A passionate educator and researcher, Dr Kalra serves as Education Editor of the International Society of Endocrinology (ISE) and is deeply involved in global endocrine education. His leadership extends to roles such as Immediate Past President of the Endocrine Society of India and Vice-President of the South Asian Federation of Endocrine Societies.
Dapiglutide is a once-weekly, subcutaneous dual GLP-1/GLP-2 receptor agonist being investigated for the treatment of obesity. This first-in-class molecule is designed to take advantage of the weight-loss effects of GLP-1 agonist and the additional benefit of a GLP-2 agonist on improving intestinal barrier function and addressing co-morbidities associated with low-grade inflammation seen in obesity.
touchENDOCRINOLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
